FDA Approves Auvelity for Agitation in Alzheimer’s Disease - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

  • By

  • Kathryn Wighton

  • April 30, 2026

  • 3 min

Share

Objective:

To report the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease.

Approach:
    Key Findings:
    • Agitation affects up to 76% of Alzheimer's patients.
    • Dextromethorphan-bupropion significantly improved agitation symptoms in clinical trials.
    • The treatment has a specific dosing regimen for agitation in Alzheimer's, differing from major depressive disorder.
    Interpretation:

    The approval of Auvelity provides a new treatment option for managing agitation in Alzheimer's patients, addressing a significant symptom that affects quality of life.

    Limitations:
    • The mechanism of action for agitation treatment remains unclear.
    • The relapse findings in ACCORD-2 should be interpreted with caution due to prior responder enrollment.
    Conclusion:

    Auvelity's approval represents a significant advancement in the treatment of agitation in Alzheimer's disease, with specific dosing and safety considerations.

    Sources:

Original Source(s)

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

  • by Kathryn Wighton

  • April 30, 2026

Related Content

Low Follow-Up After Behavioral ED Care

Follow-up occurred after fewer than 15% of mental health ED visits and about 11% of substance use–related visits in Washington Medicaid claims.

Language Processing Persists Under Anesthesia

Intraoperative recordings suggested preserved processing of speech and auditory context during unconsciousness.

Misdiagnosis Common in Parkinsonian Disorders

Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.